Treatment of Parkinson’s disease with subcutaneous lisuride infusions

  • M. Fernandez Pardal
  • Federico Micheli
  • Mabel Gatto
  • Natividad Perez y Gonzalez
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)


Four patients with Parkinson’s disease and severe fluctuating responses to levodopa and oral dopamine agonists were treated with continuous administration of lisuride infusions, administered by means of an externally worn pump.

Levodopa dosage ranged from 300 to 687mg/day and was kept stable throughout the study.

In addition increasing doses of lisuride were injected subcutaneously in the abdomen.

Lisuride doses ranged from 41 to 104µg/h.

A marked improvement in mobility was observed in every patient while severe biphasic dyskinesais almost remitted in one of them.

The most common side-effect was the presence of subcutaneous nodules appearing at the injection site.

Two cases had mild hemorrhagic complications and one initially had nausea. One patient developed acute psychiatric disturbances severe enough to be excluded from the study.

Our findings suggest that lisuride subcutaneous infusions can be useful in severily handicapped parkinsonian patients, however local and psychiatric side- effects may be a serious threat in the long-term care.


Disability Score Parkinsonian Patient Mini Mental Status Examination Score Subcutaneous Nodule Levodopa Dosage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barbeau A (1975) Long-term side effects of levodopa. Lancet 1: 395Google Scholar
  2. Barbeau A (1972) Long-term appraisal of levodopa. Neurology (Minneapolis) 22: 22–24CrossRefGoogle Scholar
  3. Barbeau A (1974) The physiology of side-effects in long term L-dopa therapy. In: Me Dowell F, Barbeau A (eds) Advances in neurology, vol 5. Raven Press, New York, pp 347–365Google Scholar
  4. Calne DB, Claveria LE, Allen J (1974) Plasma levodopa and the “On-Off” effect. In: McDowell F, Barbeau A (eds) Advances in neurology, vol 5. Raven Press, New York, pp 366–384Google Scholar
  5. Castro-Caldas A, Costa Cristina, Sampaio Cristina (1986) Lisuride infusion pump for Parkinson’s disease (Letter). Lancet 1: 1150-1151 Cotzias GC, van Woert HH, Schiffer LM (1967) Aromatic aminoacids and modification of parkinsonism. N Engl J Med 276: 374–379Google Scholar
  6. Fahn S (1974) “On-Off” phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–441PubMedCrossRefGoogle Scholar
  7. Garcia de Yébenes J, Avila C, Bazán E, Gervás J, Maseda C, Mena MA, Muradas V, Ramos J A (1982) Aspectos farmacocineticos y farmacodinámicos del tratamiento con L-dopa, más inhibidor de la dopa decarboxilasa y agonistas dopaminérgicos en la enfermedad de Parkinson. Med Clin 78: 259–264Google Scholar
  8. Gervás J, Muradas V, Bazan E et al (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282PubMedCrossRefGoogle Scholar
  9. Glough CG (1982) “On-Off” syndrome in Parksinon’s disease and intravenous levodopa. Lancet 2: 765Google Scholar
  10. Hardie RJ, Lees AJ, Stern GM (1984) “On-Off” fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 107: 487–506PubMedCrossRefGoogle Scholar
  11. Lhermitte F, Agid Y, Signoret JL, Studler J (1977) Les dyskinesies de debut et fin de dose provoqués par la L-dopa. Rev Neurol 133: 297–308PubMedGoogle Scholar
  12. Marsden CD, Parkes JD (1976) “On-Off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292–296Google Scholar
  13. Marsden CD (1977) The need for an alternative therapy in Parkinson’s disease. In: Lakke JPWF, Karf J, Wesseling H (eds) Parkinson’s disease. Concepts and prospects. Excerpta Medica, Amsterdam, pp 117–120Google Scholar
  14. Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson’s disease. Clinical Aspects. In: Marsden CD, Fahn S (eds) Movements disorders. Butterworth, London, pp 92–122Google Scholar
  15. Nutt JG, Woodward WR, Hammestad JP, Carter J, Anderson JL (1984) “On-Off” phenomenon in Parkinson’s disease. Relation to levodopa absortion and transport. N Engl J Med 310: 483–488PubMedCrossRefGoogle Scholar
  16. Obeso JA, Luquin MR, Martinez-Lage JM (1983 a) Lisuride infusion for Parkinson’s disease. Ann Neurol 14: 134Google Scholar
  17. Obeso JA, Martinez-Lage JM, Luquin MR, Bolio N (1983 b) Intravenous lisuride infusions for Parkinson’s disease. Ann Neurol 14: 252Google Scholar
  18. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470PubMedCrossRefGoogle Scholar
  19. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Intravenous lisuride corrects oscillations of motor performance in Parkinson’s disease. Ann Neurol 19: 31–35PubMedCrossRefGoogle Scholar
  20. Perret J, Ferrestein CL, Pellat J, Seore F, Gabend M, Touche M (1977) Resultats des dosages de la methoxy dopa plasmatique chez les parkinsonians induites par la L-dopa. Rev Neurol 133: 627–636PubMedGoogle Scholar
  21. Presthus J, Holmsen P (1974) Appraisal of long-term levodopa treatment of parkinsonism with special reference to therapy limiting factors. Acta Neurol Scand 50: 774–790PubMedCrossRefGoogle Scholar
  22. Quinn N, Parkes JD, Marsden CD (1982) Complicated responses fluctuations in Parkinson’s disease: response to intravenous infusion of L-dopa. Lancet 2: 992CrossRefGoogle Scholar
  23. Quinn N, Marsden CD, Parkes JD (1982) Complicated responses fluctuations in Parkinson’s disease: response to continous intravenous infusion of L-dopa. Lancet 2: 412–415PubMedCrossRefGoogle Scholar
  24. Quinn N, Parkes JD, Marsden CD (1984) Control “On-Off” phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131-1136 Shoulson I, Glaubiger GA, Chase TN (1975) “On-Off” response clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148Google Scholar
  25. Tolosa E, Martin WE, Coben JP, Jacobson RL (1975) Pattern of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177–183PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • M. Fernandez Pardal
    • 1
  • Federico Micheli
    • 1
  • Mabel Gatto
    • 1
  • Natividad Perez y Gonzalez
    • 1
  1. 1.Department of Neurology, Hospital de Clínicas José de San MartínUniversity of Buenos AiresBuenos AiresArgentina

Personalised recommendations